Xellia at a Glance
Xellia Pharmaceuticals is a global leader in providing anti-infective treatments and other critical care therapies against serious and often life-threatening conditions. Xellia is a specialty pharmaceutical company developing, manufacturing, and commercializing its anti-infective treatments and is a trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as finished dosage forms, where the majority are injectable drug products. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has approximately 1800 employees globally.
From state-of-the-art manufacturing sites in the U.S., China, Denmark, and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers.
1.5M
approximately 1.5M patients treated in 2021 with our anti-infective and critical care therapies
119
years of history, with expertise in fermented and semi-synthetic anti-infective production
500+
B2B customers in more than 70 countries and Xellia direct sales in the U.S. hospital channel
40
marketing authorizations,
8 ANDAs and 4 NDAs within critical anti-infective injectables
302.3
MUSD in revenue
▶ 48% FDF / 52% API split
20
drug products in Xellia's commercial portfolio of wich
5 are classified as critically important antimicrobials and Essential Medicines List by WHO[1]
15+
drug products in Xellia´s pipeline, consisting of anti-infectives and other critical care products
4
manufacturing sites around the globe with a solid compliance record
12
locations around the globe engaged in R&D, production and sales
≈1800
employees across functions around the globe
[1] WHO Critically Important Antimicrobials for Human Medicine 6th revision Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) November 2018.